---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-001808"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:54:52.215287+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# 10x Genomics reports preliminary Q4 rev $166M (+1% YoY); FY 2025 rev $642.8M incl. $44.1M settlements

## Summary
- Q4 consumables rev $141.7M (+6% YoY); Spatial consumables up 14% YoY to $41.0M.
- Q4 instruments rev $15.5M (-36% YoY); Single Cell instruments down 44% YoY.
- Full year rev ex-settlements $598.7M (-2% YoY); instruments rev down 39%.
- Cash & securities ~$520M at Dec 31, 2025; cumulative instruments: >6,400 Chromium, >1,500 Spatial.
- Single Cell consumables reactions sold increased >20% vs prior year.

## SEC filing metadata
- accession: 0001628280-26-001808
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000162828026001808/0001628280-26-001808-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000162828026001808/txg-20260111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-001808
- JSON: https://secwatch.observer/filing/0001628280-26-001808.json
- Plain text: https://secwatch.observer/filing/0001628280-26-001808.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.